Inhibition of monoamine oxidase (MAO) by α-ethylphenethylamine and N,α-diethylphenethylamine, two compounds related to dietary supplements

Food and Chemical Toxicology

Volumn 74, Issue , 2014, Pages 265-269

  Santillo, Michael F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

1 phenyl 2 butanamine; Amphetamines; Diethylphenethylamines; Enzyme inhibition; Monoamine oxidase (MAO); N ethyl 1 phenyl 2 butanamine

Indexed keywords

4 HYDROXYQUINOLINE; ALPHA ETHYLPHENETHYLAMINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; KYNURAMINE; METHAMPHETAMINE; N,ALPHA DIETHYLPHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PHENTERMINE; QUINOLINOL DERIVATIVE; UNCLASSIFIED DRUG; ALPHA-ETHYLPHENETHYLAMINE; BUTYLAMINE; MONOAMINE OXIDASE INHIBITOR; N,ALPHA-DIETHYLPHENYLETHYLAMINE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE; IN VITRO STUDY; ADVERSE EFFECTS; ALGORITHM; ANALOGS AND DERIVATIVES; ANALYSIS; DIET SUPPLEMENTATION; HUMAN; KINETICS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; BUTYLAMINES; DIETARY SUPPLEMENTS; HUMANS; KINETICS; METHAMPHETAMINE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PHENETHYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84910100895     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.10.009     Document Type: Article

References (42)

1. Boyer E.W., Shannon M. The serotonin syndrome. N. Eng. J. Med 2005, 352:1112-1120. 10.1056/NEJMra041867.
2. Carvalho M., Carmo H., Costa V., Capela J., Pontes H., Remião F., et al. Toxicity of amphetamines: an update. Arch. Toxicol 2012, 86:1167-1231. 10.1007/s00204-012-0815-5.
3. Cheng Y.-C., Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol 1973, 22:3099-3108. 10.1016/0006-2952(73)90196-2.
4. Cohen P.A., Travis J.C., Venhuis B.J. A methamphetamine analog (N,α-diethyl-phenylethylamine) identified in a mainstream dietary supplement. Drug Test Anal 2014, 6:805-807. 10.1002/dta.1578.
5. Copeland R.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2000, Wiley, New York. 2nd ed.
6. Dhawan K., Dhawan S., Sharma A. Passiflora: a review update. J. Ethnopharmacol 2004, 94:1-23. 10.1016/j.jep.2004.02.023.
7. Egashira T., Yamanaka Y. Changes in monoamine oxidase activity in mouse brain associated with d-methamphetamine dependence and withdrawal. Biochem. Pharmacol 1993, 46:609-614. 10.1016/0006-2952(93)90545-8.
8. ElSohly M.A., Gul W. LC-MS-MS analysis of dietary supplements for N-ethyl-α-ethyl-phenethylamine (ETH), N,N-diethylphenethylamine and phenethylamine. J. Anal. Toxicol 2014, 38:63-72. 10.1093/jat/bkt097.
9. Fleishaker J.C., Ryan K.K., Jansat J.M., Carel B.J., Bell D.J.A., Burke M.T., et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br. J. Clin. Pharmacol 2001, 51:437-441. 10.1046/j.1365-2125.2001.01367.x.
10. Fowler J.S., Logan J., Wang G.-J., Volkow N.D. Monoamine oxidase and cigarette smoking. Neurotoxicol. Teratol 2003, 24:75-82. 10.1016/S0161-813X(02)00109-2.
11. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psych 2006, 59:1046-1051. 10.1016/j.biopsych.2005.11.016.
12. Green A.L., Hait M.A.S. Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J. Pharm. Pharmacol 1978, 30:262-263. 10.1111/j.2042-7158.1978.tb13223.x.
13. Herraiz T., González D., Ancín-Azpilicueta C., Arán V.J., Guillén H. β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol 2010, 48:839-845. 10.1016/j.fct.2009.12.019.
14. Kalgutkar A.S., Dalvie D.K., Castagnoli N., Taylor T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol 2001, 14:1139-1162. 10.1021/tx010073b.
15. Kobayashi M., Pelander A., Ketola R.A., Leinonen A., Kuuranne T. Targeting misuse of 2-amino-N-ethyl-1-phenylbutane in urine samples: in vitro-in vivo correlation of metabolic profiles and development of LC-TOF-MS method. Drug Test Anal 2014, 10.1002/dta.1642.
16. Lee J., Choe S., Choi H., Heo S., Kim E., Kim H., et al. Identification of N-ethyl-α-ethylphenethylamine in crystalline powder seized for suspected drug trafficking: a research chemical or a new designer drug?. Forensic Toxicol 2013, 31:54-58. 10.1007/s11419-012-0158-1.
17. Lee J., Venhuis B., Heo S., Choi H., Seol I., Kim E. Identification and quantitation of N,α-diethylphenethylamine in preworkout supplements sold via the Internet. Forensic Toxicol 2014, 32:148-153. 10.1007/s11419-013-0205-6.
18. Lineweaver H., Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc 1934, 56:658-666. 10.1021/ja01318a036.
19. Mantle T.J., Tipton K.F., Garrett N.J. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem. Pharmacol 1976, 25:2073-2077. 10.1016/0006-2952(76)90432-9.
20. McCabe-Sellers B.J., Staggs C.G., Bogle M.L. Tyramine in foods and monoamine oxidase inhibitor drugs: a crossroad where medicine, nutrition, pharmacy, and food industry converge. J. Food Composit. Anal 2006, 19:S58-S65. 10.1016/j.jfca.2005.12.008.
21. McEnroe J., Fleishaker J. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine. Clin. Pharmacokinet 2005, 44:237-246. 10.2165/00003088-200544030-00002.
22. McKenna D.J., Towers G.H.N., Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of Ayahuasca. J. Ethnopharmacol 1984, 10:195-223. 10.1016/0378-8741(84)90003-5.
23. Michaelis L., Menten M.L. The kinetics of the inversion effect. Biochem. Z. 1913, 49:333-369.
24. Miller H.H., Shore P.A., Clarke D.E. In vivo monoamine oxidase inhibition by d-amphetamine. Biochem. Pharmacol 1980, 29:1347-1354. 10.1016/0006-2952(80)90429-3.
25. Morinan A., Garratt H.M. An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Meth 1985, 13:213-223. 10.1016/0160-5402(85)90021-X.
26. Oberlender R., Nichols D.E. Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol. Biochem. Behav 1991, 38:581-586. 10.1016/0091-3057(91)90017-V.
27. Pawar R.S., Grundel E., Fardin-Kia A.R., Rader J.I. Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC-MS/MS methods. J. Pharm. Biomed. Anal 2014, 88:457-466. 10.1016/j.jpba.2013.09.012.
28. Piazzi L., Belluti F., Bisi A., Gobbi S., Rizzo S., Bartolini M., et al. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[ω-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg. Med. Chem 2007, 15:575-585. 10.1016/j.bmc.2006.09.026.
29. Robinson J.B. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors: enantiomers of amphetamine, n-methylamphetamine and deprenyl. Biochem. Pharmacol 1985, 34:4105-4108. 10.1016/0006-2952(85)90201-1.
30. Santillo M.F., Liu Y., Ferguson M., Vohra S.N., Wiesenfeld P.L. Inhibition of monoamine oxidase (MAO) by β-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells. Toxicol. Vitro 2014, 28:403-410. 10.1016/j.tiv.2013.12.006.
31. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem. Pharmacol 1997, 54:1361-1369. 10.1016/S0006-2952(97)00405-X.
32. Sipes N.S., Martin M.T., Kothiya P., Reif D.M., Judson R.S., Richard A.M., et al. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem. Res. Toxicol 2013, 26:878-895. 10.1021/tx400021f.
33. Strolin Benedetti M., Whomsley R., Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Exp. Opin. Drug Metabol. Toxicol 2006, 2:895-921. 10.1517/17425255.2.6.895.
34. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol 2005, 75:406-433. 10.1016/j.pneurobio.2005.04.003.
35. Suzuki O., Hattori H., Asano M., Oya M., Katsumata Y. Inhibition of monoamine oxidase by d-methamphetamine. Biochem. Pharmacol 1980, 29:2071-2073. 10.1016/0006-2952(80)90493-1.
36. Ulus I.H., Maher T.J., Wurtman R.J. Characterization of phentermine and related compounds as monoamine oxidase (mao) inhibitors. Biochem. Pharmacol 2000, 59:1611-1621. 10.1016/S0006-2952(00)00306-3.
37. Uralets V., App M., Rana S., Morgan S., Ross W. Designer phenethylamines routinely found in human urine: 2-ethylamino-1-phenylbutane and 2-amino-1-phenylbutane. J. Anal. Toxicol 2014, 38:106-109. 10.1093/jat/bkt121.
38. US FDA Warning letter accessed 20.10.14. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/.
39. Venhuis B., Keizers P., van Riel A., de Kaste D. A cocktail of synthetic stimulants found in a dietary supplement associated with serious adverse events. Drug Test Anal 2014, 6:578-581. 10.1002/dta.1664.
40. Wahlstrom R., Styles C., Hagglund G. Reliable identification and quantification of three diethylphenethylamines in a Dendrobium-based dietary supplement. Anal. Meth 2014, 6:7891-7897. 10.1039/c4ay01452a.
41. Youdim M.B.H., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci 2006, 7:295-309. 10.1038/nrn1883.
42. Zametkin A., Rapoport J.L., Murphy D.L., et al. Treatment of hyperactive children with monoamine oxidase inhibitors: II. Plasma and urinary monoamine findings after treatment. Arch. Gen. Psych 1985, 42:969-973. 10.1001/archpsyc.1985.01790330049006.